SEDEMAC's Q4 profits surge 273 percent year-over-year, reaching 32.1 crore rupees as the deeptech company demonstrates strong operational execution. Operating revenues jumped 60 percent to 287.7 crore rupees, while EBITDA margins expanded significantly by over 500 basis points to 21.3 percent. The mobility segment, accounting for nearly 90 percent of top-line revenue, drove growth with electronic control unit sales climbing 63 percent to 39 lakh units. The company is scaling operations aggressively with new manufacturing facilities in Pune and Tamil Nadu, positioning itself for the next growth phase in commercial vehicles and electric segments. Separately, biotech startup Cellogen Therapeutics raised 20 crore rupees in funding to advance gene therapy programs aimed at cancer treatment with significantly lower pricing models than current market standards.
